Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Spatial analysis revealed localization of osteblastogenesis-inhibitory factors in Giant Cell Tumor of Bone

ABSTRACT: Giant cell tumor of bone (GCTB) is an intermediate malignant tumor characterized by osteolytic lesions. Although surgical resection is the mainstay of treatment, the postoperative recurrence is frequently seen, and the tumor can arise in surgically challenging locations such as the pelvis. GCTB tumor cells are not giant cells, but rather stromal cells surrounding giant cells. However, currently available pharmacological therapies are limited to indirect inhibition of bone resorption by giant cells. The mechanisms underlying the marked osteolysis and the insufficient osteogenesis—despite the usual reactive stimulation of bone formation—remain poorly understood. In this study, we employed spatial transcriptomic approaches to visualize gene expression within the tumor microenvironment of GCTB. The resulting data, integrated with immunohistochemical analyses, revealed region-specific cellular distributions and characteristic gene expression patterns, providing new insights into the survival strategies of this tumor.

ORGANISM(S): Homo sapiens

PROVIDER: GSE311123 | GEO | 2026/03/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from CD115+ preosteoclasts stimulated by conditioned medium from CT-26 cells

Project description:In osteolytic tumor, bone resportion can be occured after bone metastasis. Bone metastasis of colorectal cancer can induce obvious bone destruction. Aberrant activation of osteoclasts and the precursors is responsible for tumor-induced osteolysis. The biological process of osteoclast precursors could be modified by different tumor microenvironment. Microarrays were used to detail the differentially expressed genes or non-coding RNAs between normal osteoclast precursors and osteoclast precursors treated by secreta from CT-26 cells.

2021-08-14 | GSE182097 | GEO

Single-cell transcriptome analysis reveals T-cell exhaustion in denosumab-treated giant cell tumor of bone

Project description:Denosumab (DMAB), a human monoclonal antibody against the receptor activator of the nuclear factor-kappa B ligand, is used for the treatment for unresectable giant cell tumor of bone (GCTB). However, little is known about the molecular and functional characteristics of GCTB-infiltrating lymphocytes after DMAB treatment. Here, we performed single-cell RNA sequencing and immunostaining assays to delineate the immune landscape of GCTB in the presence and absence of DMAB. We found that exhausted CD8+ T cells were preferentially enriched in DMAB-treated GCTB. A distinct M2-skewed type of tumor-associated macrophages (TAMs) comprises the majority of GCTB TAMs. We identified cytokines, including interleukin-10, and inhibitory receptors of M2 TAMs as important mediators of CD8+ T cell exhaustion. We further revealed that DMAB treatment notably increased the expression levels of periostin (POSTN) in GCTB cells. Furthermore, POSTN expression was transcriptionally regulated by c-FOS signaling and correlated with GCTB recurrence in patients after DMAB treatment. Collectively, our findings reveal that CD8+ T-cells undergo unappreciated exhaustion during DMAB therapy and that GCTB cell-derived POSTN educates TAMs and establishes a microenvironmental niche that facilitates GCTB recurrence.

2022-10-05 | GSE212341 | GEO

Characterizing breast cancer cell biochemical responses to fluid shear in a 3D loading model

Project description:Bone is the most common site of breast cancer metastasis—only 12% of patients with skeletal metastases demonstrate a 5-year survival rate after diagnosis. Bone metastasis is characterized by a vicious cycle, where tumor-secreted factors results in increased bone turnover that often favors net bone loss. Mechanical loading, typically a bone anabolic and osteoprotective stimulus, has been shown to have positive effects on osteolytic lesions in vivo. However, the underlying mechanisms are still under investigation. Full characterization of the tumor-secreted factors that influence cancer-induced osteolysis will improve our understanding of atypical bone remodeling and mechanoresponses in tumor-induced bone disease.

2026-05-25 | GSE310741 | GEO

Single cell sequencing reveals the immunosuppressive trajectory in the tumor microenvironment of human giant cell tumor of bone

Project description:GCTB is a type of bone tumor. we used scRNA-seq analysis to investigate the tumour microenvironment (TME) in GCTB.

2024-09-30 | GSE254672 | GEO

The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing [RNA-seq]

Project description:While transcription as regulated by histones and their post-translational modifications have been well described, the connection between histone variants and changes to transcription remains poorly characterized. Potentially important insight into this process is provided by the frequently occurring mutations of H3.3, leading to G34 substitutions in childhood glioblastoma and giant cell tumor of the bone (GCTB). In this study, we have established primary cell lines from GCTB patients and used them to uncover the influence on cellular growth behavior, gene expression, and chromatin compaction. The primary cells with G34W show increased colony formation, infiltration and proliferation, hallmarks in aggressive tumor development. Isogenic cell lines with G34W recapitulated the increased proliferation observed in primary cells. Transcriptomic analysis of primary cells and biopsies suggest that most genes are downregulated, which is also reflected in increased chromatin compaction. We identified components of the spliceosome complex specifically interacting with G34W in established isogenic cell lines with a GFP-tagged H3.3. RNA-sequencing analysis and hybridization-based validations further enforced splicing aberrations. Our data uncover a role in RNA processing and chromatin modulation that is blocked by G34W, potentially driving the tumorigenic process in GCTB.

2017-10-18 | GSE103559 | GEO

The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing

2017-10-18 | GSE102193 | GEO

Genomic, transcriptomic and epigenomic profiling of GCTB

Project description:Giant cell tumor of bone is a rare bone neoplasm driven by oncogenic hotspot G34W/L/V mutations in the non-canonical histone variant H3.3. This study provides primary data of genomic (WGS), transcriptomic (RNA-seq) and epigenomic (histone mark ChIP-seq, WGBS, ATAC-seq) profiling of primary GCTB samples from several cohorts in Germany and Korea. We confirm the H3.3-G34 mutations as sole genetic drivers of GCTB, and describe the epigenetic alterations in mutant GCTB stromal cells.

| EGAS00001003730 | EGA

Osteocyte CIITA Aggravates Osteolytic Bone Lesions in Myeloma

Project description:Osteolytic destruction is a hallmark of multiple myeloma, resulting from activation of osteoclast mediated bone resorption and reduction of osteoblast-mediated bone formation. However, the molecular mechanism underlying the differentiation and activity of osteoclasts and osteoblasts within a myelomatous microenvironment remains unclear. Here, we demonstrate that the osteocyte-expressed major histocompatibility complex class II transactivator (CIITA) contributes to myeloma-induced bone lesions. CIITA upregulates the secretion of osteolytic cytokines from osteocytes through acetylation at histone 3 lysine 14 in the promoter of TNFSF11 (encoding RANKL) and SOST (encoding sclerostin), leading to enhanced osteoclastogenesis and decreased osteoblastogenesis. In turn, myeloma cell–secreted 2-deoxy-D-ribose, the product of thymidine catalyzed by the function of thymidine phosphorylase, upregulates CIITA expression in osteocytes through the STAT1/IRF1 signaling pathway. Our work thus broadens the understanding of myeloma-induced osteolysis and indicates a potential strategy for disrupting tumor-osteocyte interaction to prevent, or treat patients with, myeloma bone disease.

2022-04-23 | GSE200987 | GEO

BIGH3-induced Osteocyte Apoptosis and Gap Junction Failure Foster Osteolysis in Clear Cell Renal Cell Carcinoma (ccRCC) Bone Metastasis

Project description:Metastatic progression in bone involves crosstalk between tumor cells and osteoblasts, osteoclasts, and osteocytes. Renal cell carcinoma bone metastases (RCCBM) are predominantly osteolytic and often treatment resistant. We previously reported that inhibition of osteoblast differentiation by BIGH3 (transforming growth factor-beta-induced protein ig-h3) secreted by colonizing 786-O RCC cells promotes tumor progression in bone. Here we report that BIGH3 induces osteocyte apoptosis in both human specimens and mice and inhibits gap junction (GJ) protein Cx43 expression and function, disrupting bone homeostasis. As proof-of-concept, lysosomal inhibitors, such as hydroxychloroquine (HCQ) and NH4Cl, reversed BIGH3-mediated GJ dysfunction in vitro; and inhibited tumor growth and reversed Bo-786 RCC-induced osteolysis in vivo. HCQ in combination with CBZ, but not alone, reversed the RCCBM-mediated decreases in bone mineral density and osteoblast numbers, and decreased osteocyte apoptosis and osteoclast recruitment. These BIGH3 associated impacts on the bone microenvironment comprise a noncanonical mechanism of metastasis progression.

2024-09-18 | GSE244453 | GEO

DKK2 Mediates Osteolysis, Invasiveness, and Metastatic Spread in Ewing Sarcoma

Project description:Ewing sarcoma, an osteolytic malignancy that mainly affects children and young adults, is characterized by early metastasis to lung and bone. In this study, we identified the pro-metastatic gene DKK2 as a highly overexpressed gene in Ewing sarcoma compared with corresponding normal tissues. Using RNA interference, we showed that DKK2 was critical for malignant cell outgrowth in vitro and in an orthotopic xenograft mouse model in vivo. Analysis of invasion potential in both settings revealed a strong correlation of DKK2 expression to Ewing sarcoma invasiveness that may be mediated by the DKK effector matrix metalloproteinase 1 (MMP1). Furthermore, gene expression analyses established the ability of DKK2 to differentially regulate genes such as CXCR4, PTHrP, RUNX2, and TGFb1 that are associated with homing, invasion, and growth of cancer cells in bone tissue as well as genes important for osteolysis, including HIF1a, JAG1, IL6, and VEGF. DKK2 promoted bone infiltration and osteolysis in vivo and further analyses defined DKK2 as a key factor in osteotropic malignancy. Interestingly, in Ewing sarcoma cells, DKK2 suppression simultaneously increased the potential for neuronal differentiation while decreasing chondrogenic and osteogenic differentiation. Our results provide strong evidence that DKK2 is a key player in Ewing sarcoma invasion and osteolysis and also in the differential phenotype of Ewing sarcoma cells.

2012-12-21 | GSE36100 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data